GSTT2B and non-small cell lung carcinoma: We discovered that 36 genes were upregulated in patients with NSCLC who responded to PD-1 immunotherapy, with the top 10 most significant being GSTT2B, HMGA2, AC135050.2, ANKRD33B, MMP13, PLA2G2D, RASGEF1A, BIRC7, DCAF4L2, and CHMP7 (Figure 7).